Ascofen L (acetylsalicylic acid) tablets №10

active ingredients: 1 tablet contains acetylsalicylic acid 200 mg, paracetamol 200 mg; caffeine 40 mg;

excipients: citric acid, monohydrate; potato starch; calcium stearate

Pills.

Basic physical and chemical properties: one-piece regular round cylinders, the upper and lower surfaces of which are flat, the edges of the surfaces are beveled, with a notch for dividing on one side, white. Marbling is allowed on the surface of the tablets.

Analgesics. Other analgesics and antipyretics. Acetylsalicylic acid, combinations without psycholeptics. ATX code N02B A51.

Ascofen L (acetylsalicylic acid) has an analgesic, antipyretic and anti-inflammatory effect. The components that make up the drug enhance the effects of each other.

The antipyretic effect of acetylsalicylic acid is realized through the central nervous system by inhibiting the synthesis of prostaglandins PGF ₂ in the hypothalamus in response to exposure to endogenous pyrogens. The analgesic effect has both peripheral and central origin: peripheral effect – inhibition of the synthesis of prostaglandins in inflamed tissues; central effect – influence on the centers of the hypothalamus. Acetylsalicylic acid also reduces platelet aggregation.

Paracetamol has an analgesic, antipyretic and very weak anti-inflammatory effect, which is associated with its effect on the thermoregulatory center in the hypothalamus and a weak ability to inhibit the synthesis of prostaglandins in peripheral tissues.

Caffeine excites the central nervous system. It also enhances positive conditioned reflexes, stimulates motor activity, weakens the effect of sleeping pills and narcotic substances, enhances the effect of analgesics and antipyretics.

Not researched.

Therapy of mild or moderate pain syndrome: with headache or toothache, neuralgia, myalgia, arthralgia, primary dysmenorrhea. As an antipyretic in diseases accompanied by fever.

Hypersensitivity to the components of Ascofen L (acetylsalicylic acid), hypersensitivity to other xanthine derivatives (theophylline, theobromine), other salicylates;

– bronchial asthma, urticaria or rhinitis caused by the use of salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs), in history;

– congenital hyperbilirubinemia, severe renal or hepatic insufficiency, congenital deficiency of glucose-6-phosphate dehydrogenase, Gilbert’s syndrome;

– blood diseases, hemorrhagic diathesis, hemophilia, hypoprothrombinemia, leukopenia, anemia, increased tendency to bleeding, thrombosis, thrombophlebitis, hemorrhagic diseases;

• acute gastrointestinal ulcers; gastrointestinal bleeding; surgical interventions, accompanied by heavy bleeding;
• severe cardiovascular diseases, including rhythm disturbances, paroxysmal tachycardia, severe atherosclerosis, severe coronary heart disease, severe heart failure, acute myocardial infarction, severe arterial hypertension, portal hypertension, a tendency to vasospasm;
• states of increased arousal, sleep disturbance, old age, glaucoma, alcoholism, hyperthyroidism, acute pancreatitis, prostatic hypertrophy, severe forms of diabetes mellitus.

Use simultaneously with monoamine oxidase (MAO) inhibitors, as well as within 2 weeks after stopping their use. Combination with methotrexate at a dose of 15 mg per week or more.

Simultaneous use with tricyclic antidepressants or β-blockers.